Hepatology
Phase 2 single-arm study: Fazirsiran for liver disease associated with Alpha1-Antitrypsin deficiency.
27 Jun, 2022 | 11:19h | UTCFazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this small trial in adults with ATT deficiency, fazirsiran was associated with a strong reduction of mutant AAT levels in the serum and liver and concurrent improvements in liver enzyme levels. #ILC2022 https://t.co/RibsKzOQfO pic.twitter.com/BnMcSyfVcq
— NEJM (@NEJM) June 25, 2022
Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.
27 Jun, 2022 | 11:17h | UTCCommentary: Chronic Hepatitis B Infections Decreasing in Recent Years – HCP Live
Commentary on Twitter
New research from #GBDStudy – Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019https://t.co/e0oxlT2gKd#hepB #HBV #nohep #livertwitter @IHME_UW pic.twitter.com/V8h1LrCoUQ
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) June 21, 2022
Guideline review: EASL clinical practice guidelines: drug-induced liver injury.
22 Jun, 2022 | 11:27h | UTCOriginal Article: EASL Clinical Practice Guidelines: Drug-induced liver injury – Journal of Hepatology